Oncopeptides AB

Oncopeptides AB
About Us
Change country

Follow us:
Share:
Subscribe:

About Us

Oncopeptides is a global biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company uses its proprietary peptide-drug conjugate (PDC) platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. The first drug coming from PDC platform, PEPAXTO®(melphalan flufenamide), has been launched in the U.S., for the treatment of adult patients with relapsed or refractory multiple myeloma. Melphalan flufenamide is evaluated in a comprehensive clinical study program including the global phase 3 studies OCEAN and LIGHTHOUSE. Oncopeptides is developing several new compounds based on the PDC platform. The first one is expected to enter into clinical development in 2021.Oncopeptides has approximately 300 coworkers. The global Headquarters is based in Stockholm, Sweden and the U.S. Headquarters is situated in Boston, Mass. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO. More information is available on www.oncopeptides.com.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Number of shares and votes in Oncopeptides

Tue, Jun 30, 2020 14:00 CET

Stockholm — June 30, 2020 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of exercise of warrants under the company’s incentive programs.Through the exercise of warrants under the company’s incentive programs, the number of outstanding shares and votes have increased by 21,266 from 61,478,417 to 61,499,683. The share capital has increased by approximately SEK 2,363 from SEK 6,830,935 to SEK 6,833,298. For further information, please contact:Jakob Lindberg, CEO of OncopeptidesE-mail: jakob.lindberg@

There are no items matching the current filter

There are no more items matching the current filter

Share

About Us

Number of shares and votes in Oncopeptides

Subscribe

Media